Venus Remedies’ stock surged 10.5 per cent to close the day at Rs 188.65 on getting nod from the Drugs Controller General of India’s (DCGI) for a cancer drug.
Venus got approval to conduct Phase-1 clinical trials for its VRP 1620 molecule for the past three years. The stock opened at Rs 167.5 and made an intra-day high of Rs 192 and a low of Rs 160.1.